Rege Nephro
Develops regenerative kidney disease therapies, including RN-014, with recent funding to advance the program toward commercialization.
Overview
Rege Nephro is a regenerative medicine company focused on kidney disease, with RN-014 identified as its lead program moving toward commercialization. Its work targets patients and healthcare providers in nephrology, a market with significant unmet need for disease-modifying therapies. The company raised about $11 million in an undisclosed round announced in July 2026, described as approximately $10.6 million to advance RN-014. Although listed under AI, the available context points to a biotechnology and regenerative therapy business rather than an AI company.
Funding History
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Frequently Asked Questions
- How much funding does AI Funding track for Rege Nephro?
- AI Funding tracks $11M for Rege Nephro across 1 funding round in this database.
- What does Rege Nephro do?
- Rege Nephro is a regenerative medicine company focused on kidney disease, with RN-014 identified as its lead program moving toward commercialization. Its work targets patients and healthcare providers in nephrology, a market with significant unmet need for disease-modifying therapies. The company raised about $11 million in an undisclosed round announced in July 2026, described as approximately $10.6 million to advance RN-014. Although listed under AI, the available context points to a biotechnology and regenerative therapy business rather than an AI company.
- Where is Rege Nephro headquartered?
- Rege Nephro is headquartered in Kyoto, Japan.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.